tirzepatide class Understanding the Difference: While both peptides are powerful metabolic tools, their pharmacology is distinct: • (Manjaro): This is a dual agonist targeting GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic Tirzepatide is a first-in-class dual

Esto significa que imita a esta hormona natural que produce nuestro intestino y que nos ayuda a entender cundo estamos satisfechos despus de comer

Reach out to IBNO member, Dylan Parkinson, for more info

An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits

GLP-1 drugs as a whole were associated with a reduced risk of self-harm and substance use disorder

Patients should contact their GP or prescribing clinician if they experience: Severe or persistent abdominal pain , particularly in the upper right quadrant or radiating to the back, which could indicate biliary complications such as bile duct stones or pancreatitis Persistent vomiting that prevents adequate fluid or medication intake, risking dehydration Signs of dehydration including dark urine, dizziness, reduced urination, or extreme thirst Jaundice (yellowing of skin or eyes), which may suggest bile duct obstruction Severe diarrhoea lasting more than 48 hours or accompanied by blood Unexplained fever with abdominal symptoms Pancreatitis is a rare but serious potential side effect of GLP-1 receptor agonists

Prolonged vomiting or nausea can also lead to dehydration if fluid intake is not managed carefully